Testing the Cognitive Facilitation Effect by Dietary Supplementation of MelaGene+ Drink
NCT ID: NCT05988593
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
64 participants
INTERVENTIONAL
2022-09-01
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-aging and Anti-oxidant Efficacy Evaluation of the MelaGene
NCT05191056
Effects of Energy Drink on Repeated Sprint Performance and Cognitive Function in Athletes
NCT07104188
Evaluation of Human Efficacy of SOD Like Super Drink
NCT06322589
Nutritional Supplement's Effects on Cognition
NCT05941949
The Effect of α-GPC on Cognitive Function and Sports Performance
NCT07267845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo drink
placebo
consume one bottle (30 mL) per day
MelaGene+
MelaGene+
consume one bottle (30 mL) per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
placebo
consume one bottle (30 mL) per day
MelaGene+
consume one bottle (30 mL) per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Participants with heart, liver, kidney, endocrine and other major organic diseases (self-reported)
* Participants take drugs for a long time (self-report)
* Participants with mental illness or have undergone brain surgery
* Participants still can not clearly see words with 12pt on computer after corrected vision
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TCI Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jing-Ling Li
Role: PRINCIPAL_INVESTIGATOR
China Medical University, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Medical University
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMUH111-REC3-127
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.